Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — Investor Presentation (February 2006)

24 slides from Pharmacopeia's investor presentation, Feb 23, 2006

  1. Slide 1: Link to searchable text of slide shown above

    Slide 1: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Link to searchable text of slide shown above

  3. Slide 3: Link to searchable text of slide shown above

    Slide 3: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  4. Slide 4: Link to searchable text of slide shown above

    Slide 4: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  5. Slide 5: Link to searchable text of slide shown above

    Slide 5: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  6. Slide 6: Link to searchable text of slide shown above

    Slide 6: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  7. Slide 7: Link to searchable text of slide shown above

    Slide 7: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  8. Slide 8: Link to searchable text of slide shown above

    Slide 8: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  9. Slide 9: Link to searchable text of slide shown above

    Slide 9: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  10. Slide 10: Immunology Programs: JAK3 Inhibitors for Solid Organ Transplant

    Slide 10: Immunology Programs: JAK3 Inhibitors for Solid Organ Transplant

    Immunology Programs Pharmacopeia’ JAK3 Inhibitors for Solid Organ Transplant

  11. Slide 11: Potential Safety & Efficacy of SOT Targets

    Slide 11: Potential Safety & Efficacy of SOT Targets

    tential Safety & Efficacy of SOT Targets pramacopea HIGH 4 Efficacy importance of the target for rejection | @itarean se) Receptor Low > Safety HIGH functional selectivity for immune cells causing rejection Potential to be highly efficacious with superior safety profile

  12. Slide 12: JAK3 Inhibitors: Program Summary

    Slide 12: JAK3 Inhibitors: Program Summary

    uppressants — Pharmaco Program Summary — high value proprietary = Pharmacopeia wholly-owned = JAK is validated preclinically - involved in T-cell growth and differentiation = Therapeutic potential in transplant rejection, psoriasis, MS, asthma = Candidate in pre-clinical development in next 12 month

  13. Slide 13: Orally active blockers of T-cell activation

    Slide 13: Orally active blockers of T-cell activation

    SE MOGE}macofei’ OHr *+1Hr +4Hr Dose with Inject rl.2 and Sy Terminal blood JAKS capture antibody, Lp. collection via inhibitors, p.o cardiac puncture = 1400 = 4200 5 aD = 1000 . ia . z 300 600 . E 400: . 5 . a ‘ H 200 Aa Wr oe oe, é Laas! > SO O O ss Y © © © o_o s N s Ss S se ae ee Ce? CP SF G Oral

  14. Slide 14: Competitive landscape for JAK3 programs

    Slide 14: Competitive landscape for JAK3 programs

    = Pfizer - Psoriasis - Transplant Pre-clinical Pharmacopeia Cytopeia Novartis Aventis = Astra Zeneca = Fujisawa = Roche a J&J

  15. Slide 15: Immunology Programs: p38 Kinase Inhibitors for Rheumatoid Arthritis

    Slide 15: Immunology Programs: p38 Kinase Inhibitors for Rheumatoid Arthritis

    Immunology Programs Pharmacopeia’ p38 Kinase Inhibitors for Rheumatoid Arthritis

  16. Slide 16: p38 Rationale as Anti-Inflammatory Mechanism of Action

    Slide 16: p38 Rationale as Anti-Inflammatory Mechanism of Action

    p38 Rationale as An jammatory Mechanism of Action 30 a 2 RA - anti-TNFa RA — anti IL-1 Enbrel Remicade Kineret Humira PS 540466 in Phase | clinicals Expected to block the inflammatory effects of TNFa, IL-1B, IL-6

  17. Slide 17: p38 Kinase Inhibitors: Program Summary

    Slide 17: p38 Kinase Inhibitors: Program Summary

    38 Kinase Inhibitors — an i Program Summary — Potentially best in class = Partnered with Bristol-Myers Squibb a Inflammatory diseases including RA ~ target population of 2.1 million patients, $5.6B in US = Potent, selective drug candidate with good oral bioavailability and therapeutic index = BMS co

  18. Slide 18: p38 Kinase Inhibitors: Potential To Be Best In Class

    Slide 18: p38 Kinase Inhibitors: Potential To Be Best In Class

    p38 Kinase Inhibitors — anti-inflamimatory Prarmacopen Potential To Be Best In Class Mechanism of Action Reversible inhibitor of enzyme (BIRB-796) CNS Toxicity No CNS penetration measured (VX-745) Liver Toxicity Superior CYP-450 profile (SCIO-469) Specificity for p38 Superior kinase specificity (VX-

  19. Slide 19: Financials and Value Proposition

    Slide 19: Financials and Value Proposition

    ancial Summary Pharmacopela® Financials and Value Proposition

  20. Slide 20: Financial Data for the Months Ended December 31, 2005

    Slide 20: Financial Data for the Months Ended December 31, 2005

    Financial Data for the 12 Months Ended December 31, 2005 $20.4 million in net revenue $17.1 million in net loss Financial Data for the 3 Months Ended December 31, 2005 $5.6 million in net revenue $3.1 million in net loss Cash, Cash Equivalents & Marketable Securities on December 31, 2005 $30.4 milli

  21. Slide 21: Stock Information

    Slide 21: Stock Information

    Stock | mati Stock Exchange: Stock Symbol: Shares Outstanding (12/31/2005): 52- Week Range: Market Capitalization (2/21/2006): Enterprise Value (2/21/2006): Analyst Coverage: Pharmacopeia NASDAQ PCOP 14.99 million $3.03 - $6.06 ~ $67 million ~ $37 million Joe Paniginis - initiated10/2005 Canaccord A

  22. Slide 22: Pharmacopeia Value Proposition

    Slide 22: Pharmacopeia Value Proposition

    Pharmacopeia Value Propos Pharmacopela Portfolio Metrics Units PCOP ARQL ARRY inical Candidates/(partnered) # 33) 2(2) 21) Fredinical Candidates/(partnered) # a6) 21) 3/(0) Royalty on Main Collaboration (%) ~5 ~175 2 Library Sze (MM) >75 NA 04 Valuation (1) Units PCOP ARQL ARRY Market Capitalization

  23. Slide 23: Near Term Milestones

    Slide 23: Near Term Milestones

    Near Term Milestones iii = Within 12-months — Two internal candidates in pre-clinical development — One or more partnered programs in clinical Phase I! — Strategic partnership with significant retained rights — Core clinical-regulatory capability added — Year end cash, cash equivalents & marketable

  24. Slide 24: Program Worldwide Rights and Development Phase

    Slide 24: Program Worldwide Rights and Development Phase

    Program Worldwide Rights Lead Generation Preclinical IND Filing Optimization Development Program Partner Lead Generation Preclinical Clinical Phase NDA Filed Optimization Development I II III Searchable text section of graphics shown above [ L OGO] [LOGO] Discovering excellence, driving clinical suc

Source: SEC EDGAR · 8-K filed Feb 23, 2006

More decks from Pharmacopeia Inc